Teva puts GSK and Amarin on notice with generic Lovaza launch

Lovaza--Courtesy of GlaxoSmithKline

Watch out, GlaxoSmithKline--and Amarin. Teva Pharmaceutical Industries ($TEVA) has launched its generic version of Glaxo's ($GSK) fish-oil pill, Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease. Lovaza delivers $1.1 billion in U.S. sales for Glaxo annually, Teva says. But GSK isn't the only company likely to suffer from Teva's generic. Amarin's ($AMRN) rival product Vascepa will have to face the competition, too. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.